New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

In a patient with a Factor V Leiden heterozygous mutation but no prior thrombosis, would you consider using a JAK inhibitor for the treatment of spondyloarthritis or rheumatoid arthritis if other options have been ineffective?

1 Answer
Mednet MemberInvited Expert
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)
Answered on

1. I'd love to hear others' thoughts who are more versed in thrombotic diastheses and JAKi's.

2. The only article I could find assessing this showed no differences between the JAKi arm and the tumor necrosis factor inhibitor arm regarding patients with thrombophilia mutations (Weitz, et al., PMID 36323490).

3. This is such an unsure topic that when I did a Google search on this topic, your question came up as the 5th top link!

4. These uncontrolled systemic inflammatory diseases are so devastating ...

Join for free or sign in to see the full answer